Exelixis, Inc.

Amgen Inc.

Gisela Schwab

Steven Lacy

Khalid Ali Shah

Dana T Aftab

Colin Hessel

Christian Scheffold

Sarah S Bacus

Xiao-Dong Yang

David Haskett Lynch

Dale Miles

Alan Arroyo

Pamela Lockbaum

Mark Dean

This invention relates to a liquid pharmaceutical composition comprising cabozantinib to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma in patients in need thereof.

Liquid dosage forms to treat cancer

This invention is directed to the treatment of cancer, particularly lung cancer, breast cancer, melanoma, renal cell carcinoma, thyroid cancer that has metastasized to the bone. The invention is also directed to a method for treating bone cancer pain in an individual in need of such treatment comprising administering to the individual an effective amount of a compound of Formula I.

Method of treating cancer and bone cancer pain

This invention relates to the combination of cabozantinib and atezolizumab to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma.

Combinations of cabozantinib and atezolizumab to treat cancer

The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.

Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate

This invention provides methods for determining or predicting response to cancer therapy in an individual.

Method for predicting response to epidermal growth factor receptor-directed therapy

Growing community of inventors

Hayward, CA, United States of America

Gisela Schwab